SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Operating Margin history
Percent of revenue · from the income statement
No Operating Margin data reported for this period type.
Operating Margin vs competitors
How SGP compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 10.2% | -4.0 pp | +5.4 pp | |
| LTM Jun 2026 | 7.1% | +5.5 pp | -1.8 pp | |
| LTM Apr 2026 | -1.7% | +22.5 pp | -34.6 pp | |
| LTM Jun 2026 | -13.1% | +9.2 pp | +12.0 pp | |
| LTM Mar 2026 | -43.4% | -20.1 pp | +93.4 pp | |
| LTM Mar 2026 | -44.8% | +18.8 pp | +69.7 pp | |
| LTM Mar 2026 | -575.4% | -233.3 pp | -368.3 pp | |
| LTM Mar 2026 | -3700.9% | -3412.9 pp | -535.3 pp | |
| LTM Mar 2026 | -16741.0% | — | — | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding SGP) | -43.4% | +0.8 pp | +1.8 pp | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 612K |
| Gross Profit | (612K) |
| Gross Margin | — |
| Research & Development | 28.64M |
| Selling, General & Admin | 12.2M |
| Operating Expenses | 40.84M |
| Depreciation & Amortization | 612K |
| EBITDA | (39.26M) |
| EBITDA Margin | — |
| Operating Income | (41.45M) |
| Operating Margin | — |
| Interest Income | 3.11M |
| Interest Expense | 0 |
| Other Income / Expenses | 1.58M |
| Income Before Tax | (39.87M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (39.87M) |
| Net Margin | — |
| EPS (Basic) | (1.19) |
| EPS (Diluted) | (1.19) |
| Weighted Avg Shares | 33.43M |
| Weighted Avg Shares (Diluted) | 33.43M |
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.